Merck & Company Inc (MRK)
Official siteHEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE
Market Cap: $364.26B
Last updated: Nov 17, 2026 at 11:06 AM ET
Merck & Company Inc (MRK) Financials: Revenue, Profit and Cash Flow
Merck & Company reported revenue of $65.01B for the fiscal year ended Dec 31, 2025, up 1.3% from the year before. That year, net income was $18.26B with a net margin of 28.1%, operating cash flow was $16.47B and free cash flow was $12.36B. The quarter ended Sep 30, 2026 had revenue of $18.09B and net income of $5.07B.
Revenue and Margins
The operating margin was 32.6% in the fiscal year ended Dec 2025, the highest of the 10 years shown. Over the 9 years to Dec 2025, revenue grew from $39.81B, a compound annual rate of 5.6%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $65.01B | +1.3% | 74.8% | 32.6% | 28.1% |
| Dec 2024 | $64.17B | +6.7% | 76.3% | 31.0% | 26.7% |
| Dec 2023 | $60.12B | +1.4% | 73.2% | 3.9% | 0.6% |
| Dec 2022 | $59.28B | +21.7% | 70.6% | 30.3% | 24.5% |
| Dec 2021 | $48.70B | +17.3% | 72.0% | 25.7% | 26.8% |
| Dec 2020 | $41.52B | +6.1% | 67.2% | 12.0% | 17.0% |
| Dec 2019 | $39.12B | -7.5% | 69.3% | 18.7% | 24.9% |
| Dec 2018 | $42.29B | +5.4% | 68.1% | 19.6% | 14.6% |
| Dec 2017 | $40.12B | +0.8% | 67.8% | 15.0% | 6.0% |
| Dec 2016 | $39.81B | N/A | 64.8% | 12.2% | 9.9% |
Income Statement
In the fiscal year ended Dec 2025, net income rose 6.6% from the year before. In the quarter ended Sep 2026, net income fell 12.4% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $65.01B | $64.17B | $60.12B | $59.28B | $48.70B | $41.52B | $39.12B | $42.29B | $40.12B | $39.81B |
| Cost of revenue | $16.38B | $15.19B | $16.13B | $17.41B | $13.63B | $13.62B | $12.02B | $13.51B | $12.91B | $14.03B |
| Gross profit | $48.63B | $48.98B | $43.99B | $41.87B | $35.08B | $27.90B | $27.11B | $28.79B | $27.21B | $25.78B |
| Research and development | $15.79B | $17.94B | $30.53B | $13.55B | $12.24B | $13.40B | $9.72B | $9.75B | $10.34B | $10.26B |
| Operating income | $21.22B | $19.91B | $2.35B | $17.95B | $12.54B | $4.97B | $7.30B | $8.30B | $6.02B | $4.85B |
| Net income | $18.26B | $17.13B | $377.00M | $14.53B | $13.05B | $7.07B | $9.76B | $6.19B | $2.42B | $3.94B |
| EBITDA | $26.91B | $24.43B | $5.76B | $20.35B | $17.09B | $9.35B | $10.48B | $13.22B | $11.20B | $10.13B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $18.09B | $16.61B | $16.29B | $16.40B | $17.28B | $15.81B | $15.53B | $15.62B | $16.66B | $16.11B | $15.78B | $14.63B |
| Gross profit | $13.19B | $12.21B | $12.09B | $10.85B | $13.42B | $12.25B | $12.11B | $11.80B | $12.58B | $12.37B | $12.23B | $10.72B |
| Operating income | $5.59B | -$584.00M | -$3.40B | $3.85B | $6.51B | $4.99B | $5.87B | $4.30B | $3.93B | $6.05B | $5.64B | -$1.97B |
| Net income | $5.07B | -$1.34B | -$4.24B | $2.96B | $5.79B | $4.43B | $5.08B | $3.74B | $3.16B | $5.46B | $4.77B | -$1.23B |
Balance Sheet
As of Dec 2025, total debt of $49.34B exceeded cash and equivalents by $34.77B.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $136.87B | $117.11B | $106.67B | $109.16B | $105.69B | $91.59B | $84.40B | $82.64B | $87.87B | $95.38B |
| Current assets | $43.52B | $38.78B | $32.17B | $35.72B | $30.27B | $27.76B | $27.48B | $25.88B | $24.77B | $30.61B |
| Cash and equivalents | $14.56B | $13.24B | $6.84B | $12.69B | $8.10B | $8.05B | $9.68B | $7.96B | $6.09B | $6.51B |
| Total liabilities | $84.20B | $70.73B | $69.04B | $63.10B | $67.44B | $66.18B | $58.40B | $55.76B | $53.30B | $55.07B |
| Short-term debt | $2.59B | $2.65B | $1.37B | $1.95B | $2.41B | $6.43B | $3.61B | $5.31B | $3.06B | $568.00M |
| Long-term debt | $46.75B | $34.46B | $33.68B | $28.75B | $30.69B | $25.36B | $22.74B | $19.81B | $21.35B | $24.27B |
| Shareholder equity | $52.61B | $46.31B | $37.58B | $45.99B | $38.18B | $25.32B | $25.91B | $26.70B | $34.34B | $40.09B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $132.77B | $129.80B | $128.69B | $136.87B | $129.55B | $117.52B | $115.12B | $117.11B | $117.53B | $112.63B | $105.85B | $106.67B |
| Total liabilities | $87.83B | $87.82B | $82.75B | $84.20B | $77.64B | $68.46B | $66.72B | $70.73B | $72.97B | $68.98B | $65.42B | $69.04B |
| Cash and equivalents | $9.55B | $6.85B | $5.33B | $14.56B | $18.17B | $8.01B | $8.63B | $13.24B | $14.59B | $11.30B | $5.58B | $6.84B |
| Shareholder equity | $44.89B | $41.93B | $45.88B | $52.61B | $51.85B | $48.99B | $48.34B | $46.31B | $44.50B | $43.58B | $40.36B | $37.58B |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 75.0% of operating cash flow. Dividends and share repurchases together came to 107.3% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $16.47B | $21.47B | $13.01B | $19.09B | $13.12B | $7.62B | $8.88B | $10.92B | $6.45B | $10.38B |
| Capital expenditures | $4.11B | $3.37B | $3.86B | $4.39B | $4.45B | $4.43B | $3.37B | $2.62B | $1.89B | $1.61B |
| Free cash flow | $12.36B | $18.10B | $9.14B | $14.71B | $8.67B | $3.19B | $5.51B | $8.31B | $4.56B | $8.76B |
| Dividends paid | $8.18B | $7.84B | $7.45B | $7.01B | $6.61B | $6.21B | $5.70B | $5.17B | $5.17B | $5.12B |
| Share repurchases | $5.08B | $1.31B | $1.35B | $0 | $840.00M | $1.28B | $4.78B | $9.09B | $4.01B | $3.43B |
| Investing cash flow | -$13.74B | -$7.73B | -$14.08B | -$4.96B | -$16.42B | -$9.19B | -$2.53B | $4.31B | $2.68B | -$3.21B |
| Financing cash flow | -$1.92B | -$7.03B | -$4.81B | -$9.12B | $3.10B | -$2.83B | -$8.86B | -$13.16B | -$10.01B | -$9.04B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $6.56B | $5.37B | $3.92B | $2.86B | $7.82B | $3.29B | $2.50B | $3.45B | $9.29B | $5.64B | $3.09B | $246.00M |
| Capital expenditures | $1.04B | $893.00M | $991.00M | $1.03B | $987.00M | $764.00M | $1.33B | $937.00M | $783.00M | $791.00M | $861.00M | $989.00M |
| Free cash flow | $5.52B | $4.48B | $2.93B | $1.82B | $6.83B | $2.53B | $1.17B | $2.51B | $8.51B | $4.85B | $2.23B | -$743.00M |
Frequently Asked Questions About MRK
What is Merck & Company's annual revenue?
Merck & Company reported revenue of $65.01B for the fiscal year ended Dec 31, 2025.
How fast is Merck & Company's revenue growing?
Revenue was up 1.3% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 3.1%.
Is Merck & Company profitable?
Yes. Merck & Company reported net income of $18.26B for the fiscal year ended Dec 31, 2025, with a net margin of 28.1%.
How much free cash flow does MRK generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $16.47B minus capital expenditures of $4.11B produced free cash flow of $12.36B.
How much debt does Merck & Company have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $46.75B, short-term debt of $2.59B and cash and equivalents of $14.56B.
MRK pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts